化学科研者一站式服务平台
-
Oprozomib
N-[(2S)-3-methoxy-1-[[(2S)-3-methoxy-1-[[(2S)-1-[(2R)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide
化合物简介
Oprozomib (INN, codenamed ONX 0912 and PR-047) is an orally active second-generation proteasome inhibitor developed by Onyx Pharmaceuticals, an Amgen subsidiary. It is being investigated for the treatment of hematologic malignancies, specifically, multiple myeloma, with Phase 1b studies ongoing (as of February 16, 2016). Being an epoxyketone derivative, oprozomib is structurally related to carfilzomib and has the added benefit of being orally bioavailable. It selectively inhibits chymotrypsin-like activity of both the constitutive proteasome (PSMB5) and immunoproteasome (LMP7). Like carfilzomib, it is active against bortezomib-resistant multiple myeloma cells.
基本信息
CAS：935888-69-0
中文别名：
英文别名：ONX-0912;QC-9273;Oprozomib;PR-047;
分子式：C25H32N4O7S
分子量：532.609
精确质量：532.199
Psa：186.96
Logp：2.6684
中文别名：
英文别名：ONX-0912;QC-9273;Oprozomib;PR-047;
分子式：C25H32N4O7S
分子量：532.609
精确质量：532.199
Psa：186.96
Logp：2.6684
编号系统
UNII：MZ37792Y8J
物化性质
安全信息
生产方法及用途
合成路线
-
参考文献
Jumaa, Mouhannad; Muchamuel, Tony; Bejugam, Naveen; Wong, Hansen; Kirk, Christopher J.; Vishram Manek, Rahul; Sharma, Sanjeev Patent: US2014/113855 A1, 2014 ; Location in patent: Paragraph 0279; 0305; 0306; 0307; 0308 ;
上游原料
下游产品
图谱
1H NMR : Predict
13C NMR : Predict
